摘要
目的 探讨氨溴索雾化吸入联合孟鲁司特钠治疗难治性哮喘的临床效果.方法 选取本院2011年10月～2013年12月诊治的难治性哮喘患者114例,采用随机数字表法分为两组,57例患者采用氨溴索雾化吸入治疗为对照组,57例患者采用氨溴索雾化吸入联合孟鲁司特钠治疗为观察组,疗程2周,比较两组患者的肺功能指标改善情况、临床症状改善情况、临床疗效.结果 治疗后,两组患者的FVC、FEV1、FEV1/FVC均显著增加.观察组患者的FVC、FEV1、FEV1/FVC均明显高于对照组,观察组患者的总有效率（96.5％）明显高于对照组（82.5％）,观察组患者再次发作次数、症状缓解时间、持续发作时间均明显少于对照组,差异均有统计学意义（P＜0.05）.结论 氨溴索雾化吸入联合孟鲁司特钠难治性哮喘有效,可明显改善患者的肺功能指标和临床症状,临床疗效显著,值得临床推广应用.
Objective To investigate the clinical efficacy of ambroxol aerosol inhalation combined with montelukast in the treatment of refractory asthma. Methods 114 patients with refractory asthma diagnosed and treated in our hospital from October 2011 to December 2013 were selected and divided into two groups by the random number method.Fifty-seven patients receiving ambroxol aerosol inhalation treatment were the control group and 57 patients receiving ambroxol aerosol inhalation combined with montelukast treatment were the observation group.The treatment course was 2 weeks.The improvement of lung function parameters,improvement of clinical symptoms and clinical efficacy of the two groups were compared. Results After treatment,FVC,FEV1 and FEV1/FVC of both groups increased significantly.The observation group was significantly higher than the control group in FVC,FEV1 and FEV1/FVC.The total effective rate of the observation group （96.5%） was significantly higher than that of the control group （82.5%）.The observation group had significantly less number of times of relapse,symptom remission time,persistent onset time than the control group,with statistically significant differences （P〈0.05）. Conclusion Ambroxol aerosol inhalation combined with montelukast is an effective treatment method for refractory asthma, can significantly improve the patients＇ lung function parameters and clinical symptoms,and shows significant clinical efficacy,thereby worthy of clinical promotion and application.
出处
《中国当代医药》
2014年第29期55-57,共3页
China Modern Medicine
